Jonathan Thommis

This study investigates combining dexamethasone with PPAR agonist GW7647 to improve glucocorticoid efficacy and reduce metabolic side effects in rheumatoid arthritis models.

This study shows that targeting PPAR and ERR receptors reduces liver fat, fibrosis, and inflammation in MASLD models, suggesting a new therapeutic strategy.

The paper identifies crosstalk between ERRalpha and PPARalpha transcription factors, showing ERRalpha can act as both a repressor and activator of PPARalpha-mediated gene expression.

The paper investigates how different GR ligands affect coregulator recruitment, finding that antagonists and selective modulators reduce interactions with p300/CBP and the Mediator complex compared to full agonists.